<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-8376</journal-id>
<journal-title><![CDATA[Revista de investigación clínica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. invest. clín.]]></abbrev-journal-title>
<issn>0034-8376</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-83762023000100001</article-id>
<article-id pub-id-type="doi">10.24875/ric.22000260</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Molecular and Genetic Mechanisms of Neurotoxicity During Anti-seizure Medications Use]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gatica]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[Eric]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio-Osornio]]></surname>
<given-names><![CDATA[Moisés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Department of Neurophisiology ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Department of Neurodegenerative Diseases Laboratory ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Department of Neurochemistry ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2023</year>
</pub-date>
<volume>75</volume>
<numero>1</numero>
<fpage>1</fpage>
<lpage>12</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0034-83762023000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0034-83762023000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0034-83762023000100001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Epilepsy is a multifactorial pathology that has allowed the development of various drugs aiming to combat it. This effort was formally initiated in the 1940s when phenytoin began to be used. It eventually turned out to be a drug with great anticonvulsant efficacy. At present, several potentially good new generation anti-seizure medications (ASMs) have been developed. Most of them present more tolerability and less toxic effects. However, they continue to have adverse effects at different levels. In addition, some seizures are difficult to treat with ASMs, representing 30% of the total cases of people who suffer from epilepsy. This review aims to explore the genetic and molecular mechanisms of ASMs neurotoxicity, proposing the study of damage caused by epileptic seizures, in addition to the deterioration generated by anti-seizure drug administration within the central nervous system. It is beyond question that there is a need to develop drugs that lower the lower the risk of secondary and toxic effects of ASMs. Simultaneously, we must find strategies that produce fewer harmful interactions and more health benefits when taking anti-seizure drugs.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Seizures]]></kwd>
<kwd lng="en"><![CDATA[Anti-seizure medications]]></kwd>
<kwd lng="en"><![CDATA[Toxicity]]></kwd>
<kwd lng="en"><![CDATA[Adverse effects]]></kwd>
<kwd lng="en"><![CDATA[Epilepsy]]></kwd>
<kwd lng="en"><![CDATA[Treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thijs]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Surges]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[O'Brien]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[JW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epilepsy in adults]]></article-title>
<source><![CDATA[Lancet.]]></source>
<year>2019</year>
<volume>393</volume>
<page-range>689-701</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Higurashi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jansen]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology]]></article-title>
<source><![CDATA[Epilepsia.]]></source>
<year>2017</year>
<volume>58</volume>
<page-range>522-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Perucca]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Time to start calling things by their own names? The case for antiseizure medicines]]></article-title>
<source><![CDATA[Epilepsy Curr.]]></source>
<year>2020</year>
<volume>20</volume>
<page-range>69-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dry&#380;a&#322;owski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jó&#378;wiak]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Franckiewicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Strzelecka]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benign epilepsy with centrotemporal spikes-Current concepts of diagnosis and treatment]]></article-title>
<source><![CDATA[Neurol Neurochir Pol.]]></source>
<year>2018</year>
<volume>52</volume>
<page-range>677-89</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Löscher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Potschka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sisodiya]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Vezzani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options]]></article-title>
<source><![CDATA[Pharmacol Rev.]]></source>
<year>2020</year>
<volume>72</volume>
<page-range>606-38</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hitchings]]></surname>
<given-names><![CDATA[AW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs that lower the seizure threshold]]></article-title>
<source><![CDATA[Adverse Drug React Bull.]]></source>
<year>2016</year>
<volume>298</volume>
<page-range>1151-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinlein]]></surname>
<given-names><![CDATA[OK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ion channels and epilepsy]]></article-title>
<source><![CDATA[Am J Med Genet Semin Med Genet.]]></source>
<year>2001</year>
<volume>106</volume>
<page-range>146-59</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brunklaus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adiconis]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hession]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential excitatory vs inhibitory SCN expression at single cell level regulates brain sodium channel function in neurodevelopmental disorders]]></article-title>
<source><![CDATA[Eur J Paediatr Neurol.]]></source>
<year>2020</year>
<volume>24</volume>
<page-range>129-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escayg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Meisler]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Baulac]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huberfeld]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[An-Gourfinkel]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2]]></article-title>
<source><![CDATA[Nat Genet.]]></source>
<year>2000</year>
<volume>24</volume>
<page-range>343-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldin]]></surname>
<given-names><![CDATA[AL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nomenclature of voltage-gated sodium channels]]></article-title>
<source><![CDATA[Neuron.]]></source>
<year>2001</year>
<volume>28</volume>
<page-range>365-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Catterall]]></surname>
<given-names><![CDATA[WA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of the voltage-gated sodium channel family]]></article-title>
<source><![CDATA[Genome Biol.]]></source>
<year>2003</year>
<volume>4</volume>
<page-range>207</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hebeisen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Loureiro]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Jo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Whyment]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropharmacology Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels : a comparison with carbamazepine, oxcarbazepine and lacosamide]]></article-title>
<source><![CDATA[Neuropharmacol J.]]></source>
<year>2015</year>
<volume>89</volume>
<page-range>122-35</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panebianco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prabhakar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Marson]]></surname>
<given-names><![CDATA[AG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rufinamide add-on therapy for drug-resistant epilepsy]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev.]]></source>
<year>2020</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trimmer]]></surname>
<given-names><![CDATA[JS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subcellular localization of K+ channels in mammalian brain neurons: remarkable precision in the midst of extraordinary complexity]]></article-title>
<source><![CDATA[Neuron.]]></source>
<year>2016</year>
<volume>85</volume>
<page-range>238-56</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Combi]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potassium channels and human epileptic phenotypes : an updated overview]]></article-title>
<source><![CDATA[Front Cell Neurosci.]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baculis]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[HJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of Kv7 channels in neural plasticity and behavior]]></article-title>
<source><![CDATA[Front Physiol.]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>568667</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wulff]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[LA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Voltage-gated potassium channels as therapeutic drug targets]]></article-title>
<source><![CDATA[Nat Rev Drug Discov.]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>982-1001</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Czuczwar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wojtak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cioczek-czuczwar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Parada-turska]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maciejewski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Czuczwar]]></surname>
<given-names><![CDATA[SJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retigabine : the newer potential antiepileptic drug]]></article-title>
<source><![CDATA[Pharmacol Rep.]]></source>
<year>2010</year>
<volume>62</volume>
<page-range>211-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fedulova]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Kostyuk]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Veselovsky]]></surname>
<given-names><![CDATA[NS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two types of calcium channels in the somatic membrane]]></article-title>
<source><![CDATA[J Physiol.]]></source>
<year>1985</year>
<volume>359</volume>
<page-range>431-46</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hering]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zangerl-Plessl]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Beyl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hohaus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andranovits]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Timin]]></surname>
<given-names><![CDATA[EN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calcium channel gating]]></article-title>
<source><![CDATA[Eur J Physiol.]]></source>
<year>2018</year>
<volume>470</volume>
<page-range>1291-309</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolphin]]></surname>
<given-names><![CDATA[AC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Functions of presynaptic voltage-gated calcium channels]]></article-title>
<source><![CDATA[Function.]]></source>
<year>2021</year>
<volume>2</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alehabib]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ranji-Burachaloo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tafakhori]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramshe]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Esmaeilizadeh]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leu226Trp CACNA1A variant associated with juvenile myoclonic epilepsy with and without intellectual disability]]></article-title>
<source><![CDATA[Clin Neurol Neurosurg.]]></source>
<year>2022</year>
<volume>213</volume>
<page-range>107108</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kilaru]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Emily]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A practical guide to treatment of childhood absence epilepsy]]></article-title>
<source><![CDATA[Pediatr Drugs]]></source>
<year>2019</year>
<volume>21</volume>
<page-range>15-24</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Strong]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Function of y-aminobutyric acid receptor/channel 1 subunits in spinal cord]]></article-title>
<source><![CDATA[J Biol Chem.]]></source>
<year>2003</year>
<volume>278</volume>
<page-range>48321-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brohan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Goudra]]></surname>
<given-names><![CDATA[BG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of GABA receptor agonists in anesthesia and sedation]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2017</year>
<volume>31</volume>
<page-range>845-6</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schipper]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aalbers]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Rijkers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Swijsen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rigo]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tonic GABA a receptors as potential target for the treatment of temporal lobe epilepsy]]></article-title>
<source><![CDATA[Mol Neurobiol.]]></source>
<year>2016</year>
<volume>53</volume>
<page-range>5252-65</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Assal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Shami]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Hussein]]></surname>
<given-names><![CDATA[DE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GABA a receptors : structure, function, pharmacology, and related disorders]]></article-title>
<source><![CDATA[J Genet Eng Biotechnol.]]></source>
<year>2021</year>
<volume>19</volume>
<page-range>123</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mele]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[CB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alterations in GABA A-receptor trafficking and synaptic dysfunction in brain disorders]]></article-title>
<source><![CDATA[Front Cell Neurosci.]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>77</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wheless]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsay]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[SD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vigabatrin]]></article-title>
<source><![CDATA[J Am Soc Exp Neurother.]]></source>
<year>2007</year>
<volume>4</volume>
<page-range>163-72</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanada]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ionotropic glutamate receptors in epilepsy : a review focusing on AMPA and NMDA receptors]]></article-title>
<source><![CDATA[Biomolecules.]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>464</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sengmany]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gregory]]></surname>
<given-names><![CDATA[KJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabotropic glutamate receptor subtype 5 : molecular pharmacology, allosteric modulation and stimulus bias]]></article-title>
<source><![CDATA[Br J Pharmacol.]]></source>
<year>2016</year>
<volume>173</volume>
<page-range>3001-17</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perucca]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Perucca]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identifying mutations in epilepsy genes : impact on treatment selection]]></article-title>
<source><![CDATA[Epilepsy Res.]]></source>
<year>2019</year>
<volume>152</volume>
<page-range>18-30</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leppik]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Wechsler]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Laurenza]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials]]></article-title>
<source><![CDATA[Epilepsy Res.]]></source>
<year>2015</year>
<volume>110</volume>
<page-range>216-20</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Löscher]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basic pharmacology of valproate a review after 35 years of clinical use for the treatment of epilepsy]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2002</year>
<volume>16</volume>
<page-range>669-94</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khalil]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Alrabiah]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Rashoud]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Bari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wani]]></surname>
<given-names><![CDATA[TA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Topiramate comprehensive profile]]></article-title>
<source><![CDATA[In: Profiles of Drug Substances, Excipients, and Related Methodology]]></source>
<year>2019</year>
<volume>44</volume>
<edition>1st ed.</edition>
<page-range>333-78</page-range><publisher-loc><![CDATA[Netherlands ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paquette]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ensom]]></surname>
<given-names><![CDATA[MH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2017</year>
<volume>56</volume>
<page-range>1267-85</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shnayder]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Petrov]]></surname>
<given-names><![CDATA[KV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Juvenile myoclonic epilepsy: current state of the problem]]></article-title>
<source><![CDATA[Pers Psychiatry Neurol.]]></source>
<year>2021</year>
<volume>1</volume>
<page-range>2-20</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moosa]]></surname>
<given-names><![CDATA[AN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiepileptic drug treatment of epilepsy in children]]></article-title>
<source><![CDATA[Contin Lifelong Learn Neurol.]]></source>
<year>2019</year>
<volume>25</volume>
<page-range>381-407</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johannessen]]></surname>
<given-names><![CDATA[CU]]></given-names>
</name>
<name>
<surname><![CDATA[Johannessen]]></surname>
<given-names><![CDATA[SI.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproate: past, present, and future mechanisms of action]]></article-title>
<source><![CDATA[CNS Drug Rev.]]></source>
<year>2003</year>
<volume>9</volume>
<page-range>199-216</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isoja]]></surname>
<given-names><![CDATA[JIT]]></given-names>
</name>
<name>
<surname><![CDATA[Tapanainen]]></surname>
<given-names><![CDATA[JS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproate, hyperandrogenism, and polycystic ovaries]]></article-title>
<source><![CDATA[Dimens Contemp Ger Arts Lett.]]></source>
<year>2000</year>
<volume>57</volume>
<page-range>1064-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nanau]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Neuman]]></surname>
<given-names><![CDATA[MG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions induced by valproic acid]]></article-title>
<source><![CDATA[Clin Biochem.]]></source>
<year>2013</year>
<volume>46</volume>
<page-range>1323-38</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stinnett]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rodu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Grizzle]]></surname>
<given-names><![CDATA[WE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New developments in understanding phenytoin-induced gingival hyperplasia]]></article-title>
<source><![CDATA[J Am Dent Assoc.]]></source>
<year>1987</year>
<volume>114</volume>
<page-range>814-6</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallop]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review article: phenytoin use and efficacy in the ED]]></article-title>
<source><![CDATA[Emerg Med Australas.]]></source>
<year>2010</year>
<volume>22</volume>
<page-range>108-18</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fricke-Galindo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[LLerena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jung-Cook]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[López-López]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbamazepine adverse drug reactions]]></article-title>
<source><![CDATA[Expert Rev Clin Pharmacol.]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>705-18</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Si]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A preliminary observation of the adverse effects of phenobarbital among patients with convulsive epilepsy in rural West China]]></article-title>
<source><![CDATA[Epilepsy Behav.]]></source>
<year>2016</year>
<volume>54</volume>
<page-range>65-70</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geulayov]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fuller]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bankhead]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relative toxicity of benzodiazepines and hypnotics commonly used for self-poisoning: an epidemiological study of fatal toxicity and case fatality]]></article-title>
<source><![CDATA[J Psychopharmacol.]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>654-62</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jastrzembski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Locke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical implications and cost of electroretinography screening for vigabatrin toxicity]]></article-title>
<source><![CDATA[Can J Ophthalmol.]]></source>
<year>2020</year>
<volume>55</volume>
<page-range>e98-100</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Besag]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Vasey]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy]]></article-title>
<source><![CDATA[Pediatric Drugs]]></source>
<year>2021</year>
<volume>23</volume>
<page-range>253-86</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Medenwald]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and tolerability of rapid administration undiluted levetiracetam]]></article-title>
<source><![CDATA[Neurocrit Care]]></source>
<year>2020</year>
<volume>32</volume>
<page-range>131-4</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[MK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epigenetic effects mediated by antiepileptic drugs and their potential application]]></article-title>
<source><![CDATA[Curr Neuropharmacol.]]></source>
<year>2019</year>
<volume>18</volume>
<page-range>153-66</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pierre]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[HM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting DNA methylation]]></article-title>
<source><![CDATA[Mol Cell Biochem.]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marx]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Billups]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Billups]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maintaining the presynaptic glutamate supply for excitatory neurotransmission]]></article-title>
<source><![CDATA[J Neurosci Res.]]></source>
<year>2015</year>
<volume>1044</volume>
<page-range>1031-44</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burnashev]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Szepetowski]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NMDA receptor subunit mutations in neurodevelopmental disorders]]></article-title>
<source><![CDATA[Curr Opin Pharmacol.]]></source>
<year>2014</year>
<volume>20</volume>
<page-range>73-82</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holsapple]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Pitot]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Boobis]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Klaunig]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Pastoor]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mode of action in relevance of rodent liver tumors to human cancer risk]]></article-title>
<source><![CDATA[Toxicol Sci.]]></source>
<year>2006</year>
<volume>89</volume>
<page-range>51-6</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Deckmann]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fontes-Dutra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer-Negrini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Della-Flora Nunes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA]]></article-title>
<source><![CDATA[Food Chem Toxicol.]]></source>
<year>2018</year>
<volume>115</volume>
<page-range>336-43</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eisses]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Criscimanna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dionise]]></surname>
<given-names><![CDATA[ZR]]></given-names>
</name>
<name>
<surname><![CDATA[Orabi]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Javed]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Sarwar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproic acid limits pancreatic recovery after pancreatitis by inhibiting histone deacetylases and preventing acinar redifferentiation programs]]></article-title>
<source><![CDATA[Am J Pathol.]]></source>
<year>2015</year>
<volume>185</volume>
<page-range>3304-15</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monroy-Arreola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Durán-Figueroa]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez-Flores]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Cherit]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Watkinson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Badillo-Corona]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Up-Regulation of T-Cell activation MicroRNAs in drug-specific CD4 + T-cells from hypersensitive patients]]></article-title>
<source><![CDATA[Chem Res Toxicol.]]></source>
<year>2018</year>
<volume>31</volume>
<page-range>454-61</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio-Osornio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Retana-Márquez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Verónica Custodio]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Paz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vivo experimental models of epilepsy]]></article-title>
<source><![CDATA[Cent Nerv Syst Agents Med Chem.]]></source>
<year>2010</year>
<volume>10</volume>
<page-range>298-309</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[How]]></surname>
<given-names><![CDATA[SW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic penicillin as an experimental model of epilepsy]]></article-title>
<source><![CDATA[Exp Neurol.]]></source>
<year>1986</year>
<volume>92</volume>
<page-range>533-40</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanleenuwat]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Suntharampillai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Iwanowski]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2020</year>
<volume>81</volume>
<page-range>167-74</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bichler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Elder]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling]]></article-title>
<source><![CDATA[J Neurophysiol.]]></source>
<year>2017</year>
<volume>117</volume>
<page-range>93-103</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nigam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kumari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Batra]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colistin neurotoxicity: revisited]]></article-title>
<source><![CDATA[BMJ Case Rep.]]></source>
<year>2015</year>
<volume>2015</volume>
</nlm-citation>
</ref>
<ref id="B63">
<label>63.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grill]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Maganti]]></surname>
<given-names><![CDATA[RK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurotoxic effects associated with antibiotic use: management considerations]]></article-title>
<source><![CDATA[Br J Clin Pharmacol.]]></source>
<year>2011</year>
<volume>72</volume>
<page-range>381-93</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Bronstein]]></surname>
<given-names><![CDATA[AC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adderall® (Amphetamine-dextroamphetamine) toxicity]]></article-title>
<source><![CDATA[Top Companion Anim Med.]]></source>
<year>2013</year>
<volume>28</volume>
<page-range>2-7</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[RD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bupropion for smoking cessation in adolescents]]></article-title>
<source><![CDATA[Can Fam Physician.]]></source>
<year>2021</year>
<volume>67</volume>
<page-range>743-5</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rosiles-Abonce]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Taddei]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio-Osornio]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurotoxicity and epileptogenesis]]></article-title>
<source><![CDATA[In: Neurotox New Advances]]></source>
<year>2021</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[IntechOpen]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
